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1. Introduction
Atherosclerosis is the major cause of stroke and coro-
nary heart disease, 2 prevalent cardiovascular diseases. 
Individuals with elevated plasma low-density lipopro-
tein (LDL) cholesterol concentrations are at a higher risk 
for atherosclerotic plaque development [1]. Both free 
and fatty acid–esterified phytosterols decrease serum 
LDL cholesterol [2] and therefore reduce atherosclerosis 
disease risk. Because fatty acids have lipid-modulating 
effects, specific combinations of free fatty acids and phy-
tosterols may positively or negatively affect therapeutic 
efficacy. Furthermore, certain phytosterols may be more 
efficacious based on structural features.
The impact of individual fatty acids on phytosterol 
ester treatment efficacy has been examined in previous 
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Abstract
The dietary impact of specific phytosterols incorporated into phytosterol fatty acid esters has not been elucidated. 
Therefore, we tested the hypothesis that phytosterol esters containing different sterol moieties (sitosterol, sitostanol, 
or stigmasterol) but the same fatty acid moiety (stearic acid) produce different effects on cholesterol metabolism. Male 
Syrian hamsters were fed sitosterol, sitostanol, and stigmasterol stearate esters (25 g/kg diet) in an atherogenic diet 
containing cholesterol (1.2 g/kg) and coconut oil (80 g/kg). The phytosterol stearates produced no decrease in cho-
lesterol absorption or plasma non–high-density lipoprotein cholesterol despite a reduction in liver free cholesterol in 
hamsters fed both sitosterol and sitostanol stearate diets. In addition, sitosterol stearate significantly increased fecal 
esterified and total neutral sterol excretion. Stigmasterol stearate did not differ from control in neutral sterol excre-
tion, plasma lipids, or hepatic lipid concentration. Sitosterol stearate demonstrated the highest level of net intestinal 
hydrolysis, whereas sitostanol and stigmasterol stearate equivalently demonstrated the lowest. The cholesterol-low-
ering effect in liver—but not plasma—and the limited presence of fecal free sterols indicate that intact (unhydrolyzed) 
phytosterol stearates may impact cholesterol metabolism by mechanisms unrelated to the role of free phytosterols. 
The consumption of phytosterol esters at 2.5% of the diet elicited only modest impacts on cholesterol metabolism, al-
though sitosterol stearate had a slightly greater therapeutic impact by lowering liver free cholesterol and increasing 
esterified and total neutral sterol fecal excretion, possibly due to a greater level of intestinal hydrolysis.
Keywords: atherosclerosis, hamsters, cholesterol, cholesterol esterase, low-density lipoprotein, phytosterol ester, 
plant stanol, plant sterol, stearic acid
Abbreviations: BW, body weight; GC, gas chromatography; HDL, high-density lipoprotein; LDL, low-density lipo-
protein; non-HDL, non–high-density lipoprotein; PSE, phytosterol stearate ester
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studies. Fish oil phytosterol esters have demonstrated 
equal effectiveness as sunflower oil phytosterol esters 
in lowering LDL cholesterol but have the added benefit 
of reducing plasma triglycerides [3], indicating that the 
fish oil phytosterol esters maintain the favorable thera-
peutic effects of both the fatty acid and the phytosterol 
[4]. Phytosterols esterified to stearate-enriched fatty acid 
mixtures have demonstrated an ability to decrease LDL 
cholesterol in humans [5] and a superior plasma non–
high-density lipoprotein (non-HDL) cholesterol-lower-
ing efficacy compared with linoleate-enriched esters in 
hamsters [6]. Liberated stearic acid from phytosterol stea-
rate ester (PSE) hydrolysis in the intestine may produce 
this enhanced efficacy due to the neutral [7] or lowering 
[8] effect of stearic acid on LDL cholesterol in compari-
son to other saturated fatty acids. Although the decrease 
in non-HDL shown in hamsters fed a 0.05% (g/g) choles-
terol diet [8] may disappear at higher dietary cholesterol 
intake levels [9], stearic acid does increase fecal neutral 
sterol excretion [10], the major method of systemic cho-
lesterol elimination [11]. Because stearic acid may also 
decrease bile acid hydrophobicity [8] and increase both 
cholesterol 7α-hydroxylase activity [8] and fecal bile acid 
excretion [10], phytosterols esterified to stearic acid may 
retain these beneficial impacts on cholesterol metabo-
lism. In a previous hamster study, consumption of stea-
rate-enriched phytosterol esters caused a greater decrease 
in non-HDL cholesterol than a comparable mixture of un-
esterified stearic acid and free phytosterols [12], suggest-
ing that the beneficial effects of phytosterol stearates may 
occur through another mechanism in which complete hy-
drolysis may not be desirable.
Although the impact of the fatty acid component of 
phytosterol esters has been studied, the effect of the spe-
cific phytosterol incorporated has not been fully eluci-
dated. Mattson and coworkers [13] demonstrated equiv-
alent reductions in cholesterol absorption in rats fed 
sitosterol, campesterol, and stigmasterol oleates. How-
ever, the data may not reflect phytosterol ester efficacy 
in humans because of the use of a less sensitive animal 
model [11, 14] and a triolein emulsion rather than a hy-
percholesterolemic diet. Based on the hypocholesterol-
emic nature of stearic acid, we tested the hypothesis that 
PSEs containing different sterol moieties (sitosterol, si-
tostanol, or stigmasterol) produce different effects on 
cholesterol metabolism in male Syrian hamsters fed a 
high-cholesterol, high–saturated-fat diet. Sitosterol, stig-
masterol, and campesterol are among the most abundant 
plant sterols in nature [15] and therefore the most read-
ily available for affordable incorporation into phytos-
terol esters. Campesterol was not investigated because of 
its excessive cost and higher level of systemic absorption 
[16, 17]. Although the data remain debatable, systemi-
cally absorbed plant sterols may increase atherosclerosis 
risk [18], thus decreasing the therapeutic attractiveness of 
campesterol. Sitosterol contains a double bond at carbon 
5, whereas stigmasterol contains double bonds at carbons 
5 and 22. By focusing the current investigation on sitos-
terol, stigmasterol, and sitostanol (the saturated phytos-
terol derived from hydrogenation of either sitosterol or 
stigmasterol), we examined the impact of steroid ring 
and side chain desaturation in PSE on therapeutic effi-
cacy within Syrian hamsters fed an atherogenic diet.
2. Methods and materials
2.1. Hamsters
Thirty-nine male Syrian hamsters (Charles River Lab-
oratories, Wilmington, Mass, USA) with body masses 
ranging from 56 to 70 g were divided into experimen-
tal groups of 9 to 10 hamsters and placed in individual 
polycarbonate cages with sawdust bedding. The ham-
sters were fed ad libitum for 28 days and maintained in 
a humidity-controlled 25°C room with a 12-hour light/
dark cycle.
Hamster feed intake and body weight (BW) records 
were maintained weekly. During week 3, fecal matter 
was collected for 4 days after dual-isotope dose admin-
istration in soybean oil for cholesterol absorption mea-
surement. Bedding was collected for 7-day pooled fecal 
acidic and neutral sterol excretion analyses at the end 
of week 4. On day 28, nonfasted hamsters were eutha-
nized with CO2, the thoracic cavity was exposed by inci-
sion, and blood was collected by cardiac puncture using 
10-mL syringes before transfer to 10 mg EDTA–contain-
ing tubes on ice. Plasma was isolated by centrifugation 
at 1000g for 30 minutes at 4°C and stored at −80°C un-
til analyzed. Whole livers were excised, weighed, and 
frozen in liquid nitrogen before storage at −80°C. All 
procedures were approved by the Institutional Animal 
Care and Use Committee of the University of Nebraska.
2.2. Experimental diets
The hamsters were fed a purified, atherogenic AIN-93M 
diet high in cholesterol (1.2 g/kg) and coconut oil (80 
g/kg) [19]. This diet has been shown to induce similar 
metabolic responses and comparative pathologies to hu-
mans [20, 21]. All 4 diets contained the following (in g 
per kg): cornstarch, 379.5; dextrinized cornstarch, 155.0; 
casein, 140.0; sucrose, 100.0; coconut oil, 80.0; soybean 
oil, 20.0; cellulose, 40.0; soluble fiber (guar gum), 10.0; 
cholesterol, 1.2; AIN-93 mineral mix, 35.0; AIN-93 vita-
min mix, 10.0; l-cystine, 1.8; and choline bitartrate, 2.5. 
The PSE diets contained 25.0 g/kg of each respective 
phytosterol ester, whereas the control diet contained an 
additional 25.0 g/kg of cornstarch. The phytosterol pu-
rity of the administered PSE was determined in tripli-
cate using gas chromatography (GC) analysis after sa-
ponification, yielding purity values of 96.8% ± 2.7% for 
sitostanol stearate, 98.5% ± 0.2% for stigmasterol stea-
rate, and 76.3% ± 1.3% for sitosterol stearate (Table 1). 
Large amounts of sitosterol per se are difficult and ex-
pensive to obtain in higher purities; therefore, we de-
termined that 76.3% purity of sitosterol stearate was 
sufficient to proceed with the study. The PSEs were 
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synthesized from free phytosterols and stearoyl chloride 
purchased from TCI America (Portland, Ore, USA) as 
previously described [22]. The AIN-93 mineral and vi-
tamin mixes, casein, dextrinized cornstarch, and fibers 
were purchased from Dyets, Inc (Bethlehem, Pa, USA); 
choline bitartrate, l-cystine, and cholesterol were from 
Sigma Chemicals (St Louis, Mo, USA); and cornstarch, 
sucrose, and soybean oil were from a local grocery store. 
Diets were stored at −80°C before use.
2.3. Cholesterol absorption assay
[14C]-Cholesterol and [3H]-sitostanol were mixed into 
soybean oil for administration to hamsters as described 
by Turley et al [23] and modified by our laboratory [10, 
24]. On 2 consecutive days, the dual-isotopic mixture 
was administered to each animal by gavage; and feces 
were collected 4 days following the initial dose. Choles-
terol absorption = [([14C]/[3H] in dose − [14C]/[3H] in fe-
ces)/([14C]/[3H] in dose)] × 100%. Radiolabeled 4-[14C]-
cholesterol and 5,6-[3H]-sitostanol were purchased from 
American Radiolabeled Chemicals (St Louis, Mo, USA).
2.4. Plasma lipid analyses
Plasma total cholesterol concentration was measured en-
zymatically as previously described [25] using regents 
purchased from Roche Diagnostics (Indianapolis, Ind, 
USA). The HDL cholesterol quantification was performed 
using the total cholesterol assay after precipitation of apo-
lipoprotein-B–containing lipoproteins (Thermo Electron 
Corp, Melbourne, Australia). Non–high-density lipopro-
tein cholesterol was calculated as the difference between 
the total cholesterol and HDL cholesterol.
2.5. Liver lipid quantifications
Liver lipids were extracted using the Folch extraction 
procedure [26] as previously described [24]. Triton X-100 
(10% in chloroform; vol/vol) was added to liver lipid ex-
tracts to solubilize the lipids as previously described [25]. 
Quantification of total cholesterol, free cholesterol, phos-
pholipids, and triglycerides were performed in dupli-
cate. Total cholesterol and triglyceride reagents were pur-
chased from Roche Diagnostics (Indianapolis, Ind, USA); 
the free cholesterol and phospholipid reagents were pur-
chased from Wako Chemicals (Richmond, Va, USA). 
Liver esterified cholesterol was calculated as the differ-
ence between total and free cholesterol.
2.6. Fecal bile acid analysis
Bile acids were quantitatively extracted from feces 
using the chloroform/methanol (2:1, vol/vol) pro-
cedure of Folch et al [26] and quantified using the 
3α-hydroxysteroid dehydrogenase method as previ-
ously described [27]. β-NAD, CAPS, cholic acid, and 
3α-hydroxysteroid dehydrogenase were purchased from 
Sigma-Aldrich (St Louis, Mo, USA).
2.7. Fecal free and esterified sterol analyses
Fecal neutral sterols (cholesterol, dihydrocholesterol, co-
prostanol, and coprostanone) and phytosterols (brassicas-
terol, campesterol, stigmasterol, sitosterol, and sitostanol) 
were quantitatively extracted [26] after the addition of the 
internal standard 5α-cholestane. Free sterols were mea-
sured via direct lipid extract GC analysis [10], whereas 
esterified sterols were quantified using a modification 
of the thin-layer chromatography protocol published by 
Nissinen et al [28]. Briefly, aliquots of the lipid extracts 
were dried under nitrogen, dissolved in 50 μL of chloro-
form, and transferred to a 1 in–wide band on Whatman 
AL-SIL G thin-layer chromatography plates (aluminum-
backed, 60 Å silica, 250 μm × 20 × 20 cm; catalog no. 4420-
221) before 45 minutes of heptane/diethyl ether (50:50, 
vol/vol) mobile phase exposure. The regions correspond-
ing to esterified sterol were extracted into chloroform, sa-
ponified, and analyzed by GC [10]. All GC analyses were 
performed on an AT-5 capillary column (Alltech, Deer-
field, Ill, USA) with helium as the carrier gas, an inlet 
temp of 270°C, and a flame ionizing detector temperature 
of 300°C. The temperature program consisted of initial 
1-minute hold at 270°C followed by a 15.0°C/min tem-
perature ramp to a final 14-minute hold at 300°C.
2.8. Statistical analyses
Statistical 1-way analyses of variance were performed 
using the GLM procedure and the simulated adjust-
ment for multiple comparisons using the “/pdiff” op-
tion of “lsmeans” in SAS 9.0 (SAS Institute, Cary, NC, 
USA). The simulated adjustment was used to account 
for the different number of experimental units within 
each treatment group (control, n = 9; PSE treatments, n 
= 10). P < .05 was considered significant.
3. Results
3.1. BWs and food intake
Weekly hamster BWs and cumulative BW gain did 
not significantly differ between diets during any of the 
weeks, and the final average BW of all the hamsters in 
the study was 118 ± 1.4 g. Food intake measurements 
Table 1. Phytosterol stearate treatment purity and composition
Phytosterol Sitostanol  Stigmasterol  Sitosterol  
 stearate  stearate  stearate
 %
Campesterol 1.6 ± 1.4b 0.1 ± 0.2b 9.5 ± 0.3a
Stigmasterol 1.5 ± 1.3b 98.5 ± 0.2a 0.2 ± 0.3b
Sitosterol 0.0 ± 0.0b 1.0 ± 0.5b 76.3 ± 1.3a
Sitostanol 96.8 ± 2.7a 0.4 ± 0.5c 14.0 ± 1.2b
Treatment purity denotes the percentage of the treatment phytosterol 
within the mixture. Values are means ± SD; n = 3. Means within a row 
having different superscripts (a,b) are statistically different (P < .05).
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obtained weekly did not differ among the treatments 
for week 1, 2, or 3 (Table 2). During week 4, the con-
trol group had higher food intake compared with the si-
tostanol and stigmasterol stearate groups. However, the 
weekly average food intake was not significantly differ-
ent among any of the groups.
3.2. Intestinal cholesterol absorption
Cholesterol absorption efficiency was equivalent among 
the PSE treatment groups (sitostanol stearate, 59.9% ± 
3.0%; stigmasterol stearate, 63.0% ± 2.0%; and sitosterol 
stearate, 66.2% ± 3.0%) and did not differ significantly 
from the control (61.6% ± 3.0%).
3.3. Plasma cholesterol and liver lipid concentrations
Plasma cholesterol concentrations were unchanged by 
any of the treatments in comparison to the control after 
4 weeks (Table 3). However, differences were observed 
in liver free cholesterol concentrations (Table 4). The si-
tostanol and sitosterol stearate groups equivalently had 
the lowest liver free cholesterol compared with both the 
control and the stigmasterol stearate groups, which did 
not differ. No differences were observed in liver ester-
ified cholesterol, triglycerides, phospholipids, or liver 
wet weights among the treatment groups (Table 4).
3.4. Fecal output and fecal sterol excretion
Fecal output was significantly higher in the sitostanol 
stearate (0.979 ± 0.02 g d−1 100 g−1 BW) and sitosterol stea-
rate (0.971 ± 0.05 g d−1 100 g−1 BW) groups compared 
with the control group (0.830 ± 0.03 g d−1 100 g−1 BW). 
Stigmasterol stearate fecal output (0.931 ± 0.03 g d−1 100 
g−1 BW) did not differ significantly from any other group. 
Bile acid excretion did not differ significantly, ranging 
from 1.29 ± 0.09 μmol d−1 100 g−1 BW (sitosterol stearate) 
to 1.53 ± 0.06 μmol d−1 100 g−1 BW (stigmasterol stearate) 
(Table 5). Whereas free neutral sterol excretion was sim-
ilar among the groups, esterified and total neutral ste-
rol excretion differed significantly. The sitosterol stearate 
treatment elicited a higher esterified neutral sterol excre-
tion compared with the other diets, which did not differ. 
Sitosterol stearate total neutral sterol excretion was signif-
icantly higher than both the control and the stigmasterol 
stearate treatments but did not differ from the sitostanol 
stearate treatment despite a strong trend (P = .056). Si-
tosterol stearate elicited the highest percentage esterified 
neutral sterol excretion, whereas the stigmasterol and si-
tostanol stearate treatments did not differ despite the 
presence of an elevated percentage esterified neutral ste-
rol excretion in the stigmasterol stearate treatment com-
pared with the control (Table 5).
Free phytosterol excretion was equivalent and ele-
vated in the stigmasterol and sitosterol stearate groups 
compared with the control and the sitostanol stearate 
groups, which did not differ (Table 5). Esterified phytos-
terol excretion did not differ among the PSE treatments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
but was lowest in the control group. Total phytosterol 
excretion was equivalently greater among the PSE treat-
ments compared with the control, reflecting the in-
tended study design.
The isolated effects of added dietary PSE were exam-
ined to elucidate the excretion of the specific treatment 
phytosterol administered (Table 5). Sitosterol stearate el-
evated free treatment phytosterol excretion compared 
with sitostanol stearate but not stigmasterol stearate. Si-
tostanol stearate elicited a higher esterified treatment 
phytosterol excretion than the equivalent stigmasterol 
and sitosterol stearate treatments. Total treatment phy-
tosterol excretion was higher in the sitostanol stearate 
group compared with both the stigmasterol and sitosterol 
stearate groups, which did not differ. The percentage free 
treatment phytosterol to total treatment phytosterol was 
used as an indirect measure of net hydrolysis (Table 5). 
Sitosterol stearate elicited a greater net hydrolysis than 
the equivalent sitostanol and stigmasterol stearate treat-
ments. The PSE free phytosterol equivalent dose was cal-
Table 2. Food intake
 Control Sitostanol  Stigmasterol  Sitosterol  
  stearate    stearate    stearate
   g/d
Week 1 8.2 ± 0.5 8.7 ± 0.7 9.4 ± 1.0 8.0 ± 0.4
Week 2 12.0 ± 0.9 11.5 ± 1.0 10.9 ± 0.5 11.1 ± 0.7
Week 3 11.3 ± 0.6 12.2 ± 0.7 13.2 ± 0.4 12.2 ± 0.4
Week 4 7.5 ± 0.8a 4.2 ± 0.5b 3.2 ± 0.6b 5.3 ± 0.4a,b
Average 9.7 ± 0.6 9.2 ± 0.6 9.2 ± 0.5 9.2 ±0.3
Values are means ± SEM; n = 9 to 10. Means within a row having dif-
ferent superscripts (a,b) are statistically different (P < .05).
Table 3. Plasma lipid concentrations
 Control Sitostanol  Stigmasterol  Sitosterol  
 stearate    stearate    stearate
                          mmol/L
Total cholesterol 6.14 ± 0.23 5.67 ± 0.34 5.87 ± 0.21 5.42 ± 0.26
Non-HDL  3.83 ± 0.14 3.45 ± 0.27 3.50 ± 0.16 3.33 ± 0.17 
    cholesterol
HDL cholesterol 2.31 ± 0.17 2.21 ± 0.10 2.36 ± 0.10 2.09 ± 0.10
Values are means ± SEM; n = 9 to 10. No treatment differences were 
detected.
Table 4. Liver weight and lipid concentrations
Control Sitostanol  Stigmasterol  Sitosterol  
  stearate    stearate    stearate
                                 μmol/g
Free cholesterol 4.7 ± 0.1a 4.2 ± 0.1b 4.5 ± 0.0a 4.2 ± 0.1b
Esterified  13.1 ± 2.1 9.5 ± 1.8 14.4 ± 2.0 11.5 ± 2.2 
    cholesterol
Triglyceride 5.0 ± 0.3 5.4 ± 0.4 4.6 ± 0.3 5.6 ± 0.4
Phospholipid 13.1 ± 0.3 12.6 ± 0.3 12.8 ± 0.3 12.5 ± 0.3
                                g/100 g of BW
Liver weight 5.99 ± 0.13 5.97 ± 0.17 5.73 ± 0.14 5.92 ± 0.10
Values are means ± SEM; n = 9 to 10. Means within a row having dif-
ferent superscripts (a,b) are statistically different (P < .05).
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culated from the net hydrolysis data with the following 
formula: free phytosterol equivalent dose = [free/total 
treatment phytosterol excretion %] × [2.5% (g/g) dose × 
phytosterol molecular weight% of PSE molecular weight] 
× 100%. The free phytosterol equivalent doses (g/g) were 
0.069% (sitosterol), 0.036% (stigmasterol), and 0.013% (si-
tostanol) for the respective treatments.
4. Discussion
Results of this study indicated that phytosterol esters 
containing different sterol moieties (sitosterol, sitosta-
nol, or stigmasterol) but the same fatty acid moiety 
(stearic acid) produced different, albeit modest, effects 
on cholesterol metabolism in male Syrian hamsters. 
Liver free cholesterol concentration was significantly 
lower in hamsters fed sitosterol and sitostanol stearate 
compared with those fed stigmasterol stearate, whereas 
only sitosterol stearate caused significantly greater fecal 
neutral sterol excretion relative to sitostanol and stig-
masterol stearate treatment. Sitosterol stearate was also 
hydrolyzed in the intestine to a greater extent than the 
other PSE treatments, indicating that the sterol moiety 
interacts differently with hydrolytic enzymes. These re-
sults support the hypothesis, at least to some extent, 
that the sterol component of PSE exerts unique effects 
on certain aspects of cholesterol metabolism. In contrast, 
no treatment differences were detected in intestinal cho-
lesterol absorption, plasma cholesterol measurements, 
or fecal bile acid excretion. Although sitosterol stearate 
caused the highest amount of fecal neutral sterol ex-
cretion and lowest liver free cholesterol, these changes 
were not accompanied by lower plasma cholesterol; 
therefore, in our short-term feeding experiment, sitos-
terol stearate esters appeared to exert no greater impact 
on health benefits than PSE containing different sterols.
Our data are consistent with phytosterol-induced in-
creases in fecal neutral sterol excretion previously dem-
onstrated [29], but we did not observe the expected de-
crease in intestinal cholesterol absorption or plasma 
cholesterol reported in previous studies [6, 12]. Whereas 
stearic acid–enriched phytosterol esters fed to hamsters 
at 5% of the diet lowered non-HDL cholesterol [6], our 
2.5% PSE treatments did not lower plasma total, non-
HDL, or HDL cholesterol. In contrast, hamsters fed a 
much lower amount (0.24% of the diet) of phytosterol 
esters made with unsaturated fatty acids (canola oil) ex-
hibited reductions in plasma non-HDL cholesterol [30, 
31]. We recently reported that phytosterol esters con-
taining unsaturated fatty acids (oleate) are hydrolyzed 
in vitro to a much greater extent than phytosterol esters 
containing saturated fatty acids [22], suggesting that 
hydrolysis and liberation of free sterol may be impor-
tant factors in decreasing cholesterol absorption and/or 
plasma non-HDL cholesterol concentration.
The primary mechanism by which phytosterols lower 
cholesterol is thought to be displacement of choles-
terol from micelles by free phytosterols [32] and phy-
tosterols hydrolyzed from phytosterol esters [33]. We 
recently observed that about 90% of phytosterol oleate 
esters are hydrolyzed in vivo (unpublished observa-
Table 5. Fecal sterol excretion
 Control Sitostanol stearate Stigmasterol stearate Sitosterol stearate
 μmol d–1 100 g–1 BW
Bile acids 1.38 ± 0.06 1.41 ± 0.08 1.53 ± 0.06 1.29 ± 0.09
Neutral sterols1
Free 6.02 ± 0.32 7.39 ± 0.62 6.41 ± 0.37 6.07 ± 0.54
Esterified 0.11 ± 0.02b 0.31 ± 0.05b 0.84 ± 0.09b 3.74 ± 0.45a
Total 6.12 ± 0.31b 7.70 ± 0.64a,b 7.24 ± 0.46b 9.80 ± 0.72a
 %
Esterified/total 1.81 ± 0.40c 4.07 ± 0.55b,c 11.29 ± 0.58b 37.76 ± 3.78a
 μmol d–1 100 g–1 BW
Phytosterols2
Free 1.90 ± 0.21b 2.31 ± 0.39b 4.47 ± 0.48a 4.73 ± 0.72a
Esterified 0.05 ± 0.01b 129.74 ± 7.55a 100.71 ± 6.38a 125.59 ± 14.91a
Total 1.95 ± 0.21b 132.05 ± 7.55a 105.18 ± 6.59a 130.32 ± 14.97a
Phytosterol treatment3
Free N/A 1.13 ± 0.27b 2.30 ± 0.32a,b 3.51 ± 0.48a
Esterified N/A 129.74 ± 7.55a 91.48 ± 6.03b 85.97 ± 12.05b
Total N/A 130.87 ± 7.55a 93.77 ± 6.15b 89.47 ± 12.13b
 %
Free/total4 N/A 0.88 ± 0.22b 2.45 ± 0.31b 4.68 ± 0.90a
Values are means ± SEM; n = 9 to 10. N/A indicates not applicable because of no added phytosterols in diet. Means within a row 
having different superscripts (a,b,c) are statistically different (P < .05).
1 Sum of cholesterol, dihydrocholesterol, coprostanol, and coprostanone.
2 Sum of brassicasterol, campesterol, stigmasterol, sitosterol, and sitostanol.
3 Phytosterol treatment indicates quantification of the specific treatment phytosterol only.
4 Free treatment phytosterol to total treatment phytosterol ratio is referred to as net hydrolysis.
542 As h, hA n g, Dus s A ul t, & CA r r i n Nut r i ti o N res ea r c h 31 (2011) 
tions), whereas the current study indicated that a max-
imum of 4.68% of sitosterol stearate ester is hydrolyzed. 
When fed PSE at 2.5% of the diet—assuming approxi-
mately 5% hydrolysis and the fact that the sterol moiety 
is 60% of PSE mass—the maximum amount of free phy-
tosterol liberated from hydrolysis would be equivalent 
to feeding free phytosterol at 0.075% of the diet. In com-
parison, feeding 0.24% phytosterol esters made with un-
saturated fatty acids [30, 31], assuming 90% hydrolysis, 
would be equivalent to feeding free phytosterol at 0.13% 
of the diet. If cholesterol-lowering efficacy is indeed de-
pendent on the presence of free phytosterol, then our 
treatment using stearate esters may have had the disad-
vantage of resisting hydrolysis and limiting the amount 
of free phytosterol.
The current results seem to contradict our previous 
study demonstrating significant cholesterol lowering 
in hamsters consuming PSE at 5% of the diet [6, 12]. 
However, because intact phytosterol esters do not in-
corporate into micelles or affect cholesterol solubility 
within mixed micelles in vitro [34], unhydrolyzed phy-
tosterol esters may affect cholesterol absorption inde-
pendent of micelles by creating a lipid phase in which 
cholesterol becomes trapped. Indirect evidence for this 
can be inferred by decreased cholesterol absorption in 
triglyceride lipase knockout mice fed a high-choles-
terol, high-fat diet [35]. As we previously observed, 
the superior cholesterol lowering of presumably in-
tact 5% stearate-enriched phytosterol esters compared 
with a completely hydrolyzed treatment (consumed as 
3.0% free phytosterols and 2.0% stearic acid) [12] sup-
ports the presence of a separate phytosterol stearate 
mechanism.
In the present study, sitosterol stearate esters elic-
ited a slightly greater positive effect on cholesterol me-
tabolism than the other PSEs consumed at 2.5% of the 
diet by increasing fecal neutral sterol excretion and 
lowering liver free cholesterol. Our data suggest that 
the cholesterol-lowering abilities of PSEs may involve 
mechanisms in addition to simple displacement of cho-
lesterol from micelles. When consumed by hamsters 
at 2.5% of the diet, sitosterol stearate esters appeared 
to be the most efficacious PSE despite only a mod-
est impact upon cholesterol metabolism. At this level 
of intake, the short-term health benefits of sitosterol 
stearate esters appear to be minimal, although the met-
abolic impact of PSE long-term treatment should be 
investigated.
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